Sensei Biotherapeutics announced that it has changed its corporate name to Faeth Therapeutics, reflecting the company’s focus on advancing PIKTOR, an investigational oral therapy designed to target the PI3K/AKT/mTOR pathway, one of the most frequently altered pathways in cancer.
The company’s common stock is expected to begin trading on the Nasdaq Capital Market under the ticker symbol “FTH” on June 16, 2026. The transition follows stockholder approval of the conversion of Series B preferred stock issued in connection with the February 2026 acquisition of Faeth Therapeutics and a concurrent private placement that generated approximately $200 million in gross proceeds.
Faeth said it is now positioned as a well-capitalized public company with a focused clinical pipeline and several upcoming catalysts. Its lead candidate, PIKTOR, is an all-oral combination of serabelisib, a selective PI3K-alpha inhibitor, and sapanisertib, an mTORC1/mTORC2 inhibitor. The treatment is designed to inhibit multiple nodes within the PI3K/AKT/mTOR pathway, potentially delivering deeper and more durable responses.
PIKTOR is currently being evaluated in a Phase 2 study in second-line advanced endometrial cancer, with topline data expected during the second half of 2026. The company is also conducting a Phase 1b/2 trial in HR+/HER2-negative advanced breast cancer, with interim data anticipated in 2027.
The company also announced changes to its executive team and board. Faeth co-founder Anand Parikh was appointed Chairman, President and Chief Executive Officer, while Brian Stephenson, Ph.D., CFA, became Chief Financial Officer. The board was strengthened with the additions of former U.S. Food and Drug Administration Commissioner Stephen M. Hahn, M.D., and life sciences advisor Saira Ramasastry.
Faeth was founded in 2019 and focuses on developing therapies based on multi-node inhibition of key oncogenic pathways. Its scientific founders include Lewis Cantley, Ph.D., Siddhartha Mukherjee, M.D., D.Phil., Karen Vousden, Ph.D., Scott Lowe, Ph.D., and Greg Hannon, Ph.D.
KEY QUOTES:
“Starting tomorrow, we will begin trading on Nasdaq under our new name and ticker as a well-capitalized public company backed by a syndicate of leading life sciences investors, and focused on a clear set of clinical catalysts. For two decades, drugs that block a single node of the PI3K/AKT/mTOR pathway have been undone by the tumor’s ability to route around them. PIKTOR represents our answer to this challenge: an all-oral regimen that patients can take at home, designed to inhibit PI3K-alpha, mTORC1 and mTORC2 at once, close the routes tumors may use to escape, and potentially drive deeper, more durable suppression, with the potential for a best-in-class profile. We believe we now have the capital and the team to put that approach to the test, beginning with topline Phase 2 data in advanced endometrial cancer, expected in the second half of this year, and interim Phase 1b/2 data in HR+/HER2- advanced breast cancer, expected in 2027.”
Anand Parikh, Chairman and Chief Executive Officer of Faeth Therapeutics
“In a career spent in oncology and at the FDA, I’ve learned how rarely a program pairs a high-prevalence target with a potentially differentiated mechanism. I believe Faeth’s multi-node, all-oral approach to the PI3K/AKT/mTOR pathway is scientifically rigorous and aimed at a real unmet need. I’m looking forward to guiding the company through this next stage of clinical development.”
Stephen M. Hahn, M.D., 24th Commissioner of the U.S. Food and Drug Administration and Member of the Board of Directors of Faeth Therapeutics
